The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research
With Novo Nordisk success, is there a "Nokia risk" for Denmark?
How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company
Novo Nordisk CEO on Wegovy, Ozempic, Profit Forecast, US Market
How Novo Nordisk built an empire selling diabetes and weight-loss drugs
NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages
TIME100 Most Influential Companies: Novo Nordisk
In 2024 Team Novo Nordisk gears up with science #jerseyreveal
Novo Nordisk shares sink on medicare price negotiation fears
Introduction to Novo Nordisk's Graduate Programme
What Novo Nordisk's Ozempic Success Means for Denmark
The Novo Nordisk Foundation
'Attractive' growth ahead for Novo Nordisk, CEO says
The spirit of our founders: The values and mindsets that created Novo Nordisk a century ago
Novo Nordisk is scaling Wegovy supply 'significantly': CFO
Novo Nordisk: Everything investors need to know
Novo Nordisk, Eli Lilly have strong first-mover advantage: analyst
Novo Nordisk CEO testifies before Senate on weight loss drug prices
Cramer’s Stop Trading: Novo Nordisk
Team Novo Nordisk is Racing With Diabetes